Method for treating an asthma attack

Information

  • Patent Grant
  • 8640711
  • Patent Number
    8,640,711
  • Date Filed
    Thursday, December 9, 2010
    13 years ago
  • Date Issued
    Tuesday, February 4, 2014
    10 years ago
Abstract
A method for treating the lung during an acute episode of reversible chronic obstructive pulmonary disease such as an asthma attack. The method comprises transferring energy to an airway wall of an airway such that a diameter of the airway is increased. The energy may be transferred to the airway wall prior to, during or after an asthma attack. The energy may be transferred in an amount sufficient to temporarily or permanently increase the diameter of the airway. The method may be performed while the airway is open, closed or partially closed.
Description
BACKGROUND

Asthma is a serious chronic condition affecting an estimated 10 million Americans. Asthma is characterized by (i) bronchoconstriction, (ii) excessive mucus production, and (iii) inflammation and swelling of airways. These conditions cause widespread and variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe. Asthma further includes acute episodes or attacks of additional airway narrowing via contraction of hyper-responsive airway smooth muscle. Other obstructive diseases such as COPD may also have a reversible component caused by one or more of the above mentioned three elements.


Asthma generally includes excessive mucus production in the bronchial tree. Usually, there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. Excessive amounts of mucus are found in the airways and semisolid plugs of mucus may occlude some small bronchi. Also, the small airways are narrowed and show inflammatory changes. The reversible aspects of COPD include partial airway occlusion by excess secretions, and airway narrowing secondary to smooth muscle contraction, bronchial wall edema and inflammation of the airways.


In asthma, chronic inflammatory processes in the airway play a central role in increasing the resistance to airflow within the lungs. Many cells and cellular elements are involved in the inflammatory process, particularly mast cells, eosinophils T lymphocytes, neutrophils, epithelial cells, and even airway smooth muscle itself. The reactions of these cells result in an associated increase in the existing sensitivity and hyper-responsiveness of the airway smooth muscle cells that line the airways to the particular stimuli involved.


The chronic nature of asthma can also lead to remodeling of the airway wall (i.e., structural changes such as thickening or edema) which can further affect the function of the airway wall and influence airway hyper-responsiveness. Other physiologic changes associated with asthma include excess mucus production, and if the asthma is severe, mucus plugging, as well as ongoing epithelial denudation and repair. Epithelial denudation exposes the underlying tissue to substances that would not normally come in contact with them, further reinforcing the cycle of cellular damage and inflammatory response.


In susceptible individuals, asthma symptoms include recurrent episodes of shortness of breath (dyspnea), wheezing, chest tightness, and cough. Currently, asthma is managed by a combination of stimulus avoidance and pharmacology.


Stimulus avoidance is accomplished via systematic identification and minimization of contact with each type of stimuli. It may, however, be impractical and not always helpful to avoid all potential stimuli.


Asthma is managed pharmacologically by: (1) long term control through use of anti-inflammatories and long-acting bronchodilators and (2) short term management of acute exacerbations through use of short-acting bronchodilators. Both of these approaches require repeated and regular use of the prescribed drugs. High doses of corticosteroid anti-inflammatory drugs can have serious side effects that require careful management. In addition, some patients are resistant to steroid treatment. The difficulty involved in patient compliance with pharmacologic management and the difficulty of avoiding stimulus that triggers asthma are common barriers to successful asthma management. Thus, current management techniques are neither completely successful nor free from side effects.


In view of the foregoing, a non-pharmacological asthma treatment which does not rely on avoiding stimuli is desirable.


SUMMARY OF THE INVENTION

The invention is a method for treating lung disease and in particular, a method for treating the lung during an acute episode of reversible obstructive pulmonary disease such as an asthma attack. One embodiment of the present invention includes a method for treating asthma comprising the step of transferring energy to an airway wall of an airway in a lung such that a diameter of the airway is increased. The energy may be transferred to the airway wall prior to, during or after an asthma attack. The energy may also be transferred in an amount sufficient to temporarily or permanently increase the effective diameter of the airway. The method may be performed while the airway is open, closed or partially closed.


In another embodiment of the invention, a method for treating asthma in a lung having a constricted airway comprises transferring energy to an airway wall of the constricted airway sufficient to open the airway. The energy transferred may be in an amount sufficient to permanently or temporarily open the constricted airway. The method may be performed to open a wholly constricted airway as well as a partly constricted airway.


In yet another variation of the invention, a method for treating lung disease comprises transferring energy to an airway wall to alter the airway wall in such a manner that a resistance to airflow of the airway is decreased. The method may be performed by transferring energy to increase the caliber of the airway. The airway wall may also be altered by decreasing a thickness of the airway wall. The energy may be transferred to the airway wall during an asthma attack.


In another variation of the invention, the method comprises manipulating a distal portion of an energy delivery apparatus to a first location along the airway prior to applying the energy. The energy delivering apparatus can include a rounded tip sufficiently flexible such that when the tip encounters a closed or partially closed airway, trauma to the airway is minimized. The energy is then applied to a discrete location while the distal portion of the energy delivery apparatus is stationary. The distal portion can then be moved to a new location and the process repeated until a number of discrete locations have been treated. In an alternative, the method comprises moving the distal portion of the energy delivery apparatus from the first location and applying energy while the distal portion is being moved in the airway.


In another variation of the present invention, a method comprises transferring energy to or from an airway wall to treat a lung disease such as asthma. The method may be carried out by inserting into the airway an apparatus having a cryogenic tip or other cooling means capable of transferring energy from the tissue, resulting in a desired condition such as a larger diameter airway.


In yet another variation of the invention, a combination of the above discussed techniques are carried out such that at one time, energy is applied while the distal portion of the energy delivery device is being moved and at another time, energy is applied when the distal portion of the apparatus is stationary.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in greater detail with reference to the various embodiments illustrated in the accompanying drawings wherein:



FIG. 1. is a cross sectional view of an airway in a healthy lung;



FIG. 2. shows a section through a bronchiole having an airway diameter smaller than that shown in FIG. 1;



FIG. 3 illustrates the airway of FIG. 1 in which the smooth muscle has hypertrophied and increased in thickness causing reduction of the airway diameter;



FIG. 4 is a schematic side view of the lungs being treated with a treatment device as described herein;



FIG. 5 is a partial view of an energy delivery device which can be used to carry out the method of the invention; and



FIG. 6 is a partial view of a thermocouple attached to an energy delivering device in accordance with the invention.





DETAILED DESCRIPTION

This invention relates to methods for improving airflow through the airways of a lung having reversible obstructive pulmonary disease. In accordance with the invention an airway may be treated during an acute episode of reversible obstructive pulmonary disease such as an asthma attack. The invention comprises applying or transferring energy to an airway wall to increase the diameter of the airway or otherwise reduce resistance to airflow through the airway. The energy may be transferred in an amount sufficient to temporarily or permanently increase the diameter of the airway. Notably, the method may be performed while the airway is open, closed or partially closed. The inventive method thus can “rescue” an asthma sufferer during an acute asthma episode by increasing the diameter of a constricted airway.


Various airways are shown in FIGS. 1-3. FIGS. 1 and 2 show a cross section of two different airways in a healthy patient. The airway of FIG. 1 is a medium sized bronchus having an airway diameter D1 of about 3 mm. FIG. 2 shows a section through a bronchiole having an airway diameter D2 of about 1.5 mm. Each airway includes a folded inner surface or epithelium 10 surrounded by stroma 12 and smooth muscle tissue 14. The airway is thus quite different from other tissues such as blood vessel tissue which does not include such folds. The larger airways including the bronchus shown in FIG. 1 also have mucous glands 16 and cartilage 18 surrounding the smooth muscle tissue 14. Nerve fibers 20 and blood vessels 24 surround the airway.



FIG. 3 illustrates the bronchus of FIG. 1 in which the smooth muscle 14 has hypertrophied and increased in thickness causing the airway diameter to be reduced from the diameter D1 to a diameter D3. Accordingly, the airways to be treated with the device of the present invention may be 1 mm in diameter or greater. The airways to be treated are often second to eighth generation, and more preferably airways of the second to sixth generation.



FIG. 4 is an illustration of the lungs being treated with a system 36 which can be used to carry out the present invention. The system 36 includes a controller 32 and an energy treatment device 30 which may be an elongated member as described further below. The device 30 also includes an expandable distal section which can be positioned at a treatment site 34 within a lung or another target medium. In operation, the device is manipulated to the treatment site 34. RF energy, for example, is delivered through the energy delivering device and penetrates the surface of the lung tissue such that tissue is affected below the epithelial layer as well as on the surface of the lung tissue. The application of energy may cause a variety of structural and physiological effects which may result from the application of energy to the airway wall. For example, application of energy to the airway smooth muscle of an asthmatic patient can debulk or otherwise reduce the volume of smooth muscle. This reduced volume of smooth muscle increases the airway diameter for improved air exchange. Even small increases in the airway size can provide relief as the resistance to airflow varies inversely with approximately the fourth power of diameter.


Application of energy to an airway wall can also reduce inflammation in the inner lung tissue. Reducing inflammation and edema of the tissue surrounding the airway can increase the diameter of an airway. Inflammation and edema (accumulation of fluid) of the airway are chronic features of asthma. The inflammation and edema can be reduced by application of energy to stimulate wound healing and regenerate normal tissue. Healing of the epithelium or sections of the epithelium experiencing ongoing denudation and renewal allows regeneration of healthy epithelium with less associated airway inflammation. The less inflamed airway has an increased airway diameter both at a resting state and in constriction. The wound healing can also deposit collagen which improves parenchymal tethering.


Application of energy to an airway wall can also inhibit the release of inflammatory mediators in the airway wall which may serve as a stimulus for airway smooth muscle contraction. Therapy that reduces the production and release of inflammatory mediators can reduce smooth muscle contraction, inflammation of the airways, and edema. Examples of inflammatory mediators are cytokines, chemokines, and histamine. The tissues which produce and release inflammatory mediators include airway smooth muscle, epithelium, and mast cells. Thus, treatment of these structures with energy can reduce the ability of the airway structures to produce or release inflammatory mediators. The reduction in released inflammatory mediators will reduce chronic inflammation, thereby increasing the airway inner diameter, and may also reduce hyper-responsiveness of the airway smooth muscle.


Application of energy to an airway wall can also increase the airway diameter by damaging nerve tissue in the airways. This follows because a resting tone of smooth muscle is nerve regulated by release of catecholamines. Thus, by damaging or eliminating nerve tissue in the airways the resting tone of the smooth muscle is reduced, and the airway diameter is increased.


Application of energy to the airways may cause other physiological responses which result in increased diameters. It is to be understood, however, that the invention is not limited to a certain physiological response or process except where such a physiological response or process is a claim limitation in the appended claims.


As shown in FIG. 4, the present invention may be performed using a controller 32 and a device 30 through which it delivers energy to the target medium 34. A device 30 of the present invention should be of a size to access the bronchus or bronchioles of the human lung. The device may be sized to fit within bronchoscopes, preferably, with bronchoscopes having a working channel of 2 mm or less. The device may also include a steering member configured to guide the device to a desired target location. For example, this steering member may deflect a distal tip of the device in a desired direction to navigate to a desired bronchi or bronchiole.


Another aspect of the present invention is to treat more than one location. Several to many locations (e.g., reference numerals 31, 34 and 38) in the airways may be treated in order to reduce asthmatic symptoms. This can be accomplished by manipulating or positioning the expandable basket at a target site in the airways, expanding the expandable basket such that the energy transfer elements (e.g., the basket legs) contact the airway wall, and then delivering energy to the airway wall. The expandable basket is preferably collapsed and moved to another location and the process is repeated. This technique for applying energy at discrete locations can be repeated as many times as necessary to treat the asthmatic symptoms.


The present invention also includes applying energy continuously along an airway as an expanded basket is moved along the airway. Specifically, the basket may be deployed, energized, and then moved along the airway continuously to continually transfer energy to or from the airway wall as the basket is moved axially along the airway. The above described methods may also be used in combination with one another.


An exemplary partial view of an energy delivering device which may be used to perform the invention is shown in FIG. 5. The energy delivering apparatus 30 typically includes an elongate body having a proximal section and a distal section. The distal section features a radially expandable basket having a plurality of legs 106. The legs may be electrodes or have an active region defined by an insulated covering which contacts the medium to be treated. The basket is expanded with an actuator mechanism 112 which may be activated by a movable lever in a handle attached to the proximal end of the elongate body.


The invention may also include an atraumatic tip 200 to ensure that the invention does not injure airway tissue when it is placed into airways that are partially or completely closed. The tip may be formed of a flexible material and/or may be rounded to minimize trauma. Examples of energy delivering devices in accordance with the present invention are described in co-pending U.S. application Ser. No. 09/436,455 filed Nov. 8, 1999 which is hereby incorporated by reference in its entirety. Other examples of devices and methods which may be used in accordance with the present invention are found in the following U.S. patent applications: Ser. No. 09/095,323—Methods and Apparatus for Treating Smooth Muscles in the Walls of Body Conduits; Ser. No. 09/349,715—Method of Increasing Gas Exchange of a Lung; and Ser. No. 09/296,040—Devices for Modification of Airways By Transfer of Energy. The entirety of each of the aforementioned applications is hereby incorporated by reference. Another suitable energy device is described in International patent application no PCT/US00/28745.


The energy delivery device may further comprise a temperature detecting element. Examples of temperature detecting elements include thermocouples, infrared sensors, thermistors, resistance temperature detectors (RTDs), or any other apparatus capable of detecting temperatures or changes in temperature. The temperature detecting element is preferably placed in proximity to the expandable member.



FIG. 5 is a partial view of a variation of the energy delivery device having thermocouple 137 positioned about midway along basket leg 106. FIG. 6 is an enlarged partial view of the thermocouple 137 of FIG. 5 showing the leads 139 separately coupled on an inwardly-facing surface of the leg 106. Consequently, the basket leg itself is used as part of the thermocouple junction upon which the temperature measurement is based. The thermocouple junction is intrinsic to the basket leg. This configuration is preferred because it provides an accurate temperature measurement of tissue contacting the leg 106 in the vicinity of the thermocouple leads. In contrast, typical thermocouple configurations consist of a thermocouple junction offset or extrinsic to the basket leg. Thermocouple junctions offset or extrinsic to the basket leg do not measure temperature as accurately in certain applications as thermocouple junctions which are intrinsic to the basket leg.


An intrinsic thermocouple junction configuration is safer than an extrinsic thermocouple junction because, in the event one of the thermocouple leads separates from a basket leg, the intrinsic thermocouple junction becomes “open” and no thermocouple signal is produced. In contrast, when an extrinsic thermocouple junction separates from a basket leg a signal continues to be produced. The signal of a detached extrinsic thermocouple junction can be misleading because although a temperature reading continues to be produced, the temperature reading does not reflect the temperature at the point where the basket leg contacts the subject tissue. Accordingly, an intrinsic thermocouple junction having two leads separately attached to a basket leg is preferred.



FIG. 6 also shows basket leg 106 having an outer insulating material or coating 410. The boundaries 415 of the insulating material 410 define an uninsulated, active section of electrode leg 106 which delivers energy to the airway walls. Preferably, the insulating coating 410 is heat shrink tubing or a polymeric coating. However, other insulating materials may be used.


Various controllers may be used to carry out the invention. An example of an RF controller which may be used to carry out the invention is described in co-pending International Patent Application No. PCT (not yet assigned), entitled “CONTROL SYSTEM AND PROCESS FOR APPLICATION OF ENERGY TO AIRWAY WALLS AND OTHER MEDIUMS” filed Oct. 17, 2001 incorporated herein by reference in its entirety.


The controller and power supply is configured to deliver enough energy to produce a desired effect in the lung. The power supply should also be configured to deliver the energy for a sufficient duration such that the effect persists. This may be accomplished by a time setting which may be entered into the power supply memory by a user.


The power supply or generator may also employ a number of algorithms to adjust energy delivery, to compensate for device failures (such as thermocouple detachment), to compensate for improper use (such as poor contact of the electrodes), and to compensate for tissue inhomogeneities which can affect energy delivery such as, for example, subsurface vessels, adjacent airways, or variations in connective tissue.


The power supply can also include circuitry for monitoring parameters of energy transfer: (for example, voltage, current, power, impedance, as well as temperature from the temperature sensing element), and use this information to control the amount of energy delivered. In the case of delivering RF energy, typical frequencies of the RF energy or RF power waveform are from 300 to 1750 kHz with 300 to 500 kHz or 450 to 475 being preferred. The RF power-level generally ranges from about 0-30 W but depends upon a number of factors such as the size and number of the electrodes. The controller may also be configured to independently and selectively apply energy to one or more of the basket leg electrodes.


A power supply may also include control modes for delivering energy safely and effectively. Energy may be delivered in open loop (power held constant) mode for a specific time duration. For example, a power setting of 8 to 30 Watts for up to 10 seconds is suitable and a power setting of 12 to 30 Watts for up to 5 seconds is preferred. For more permanent restructuring of the airways, a power setting of 8 to 15 Watts for 5 to 10 seconds is suitable. For mere temporary relief or enlargement of the airway, a power setting of 10 to 25 Watts for up to 3 seconds is suitable. With higher power settings, correspondingly lower time durations are preferred to limit collateral thermal damage.


Energy may also be delivered in temperature control mode, with output power varied to maintain a certain temperature for a specific time duration. For example, energy may be delivered for up to 20 seconds at a temperature of 55 to 80 degrees C., and more preferably, energy is delivered up to 10 seconds at a temperature in the range of 60 to 70 degrees C. For more permanent restructuring of the airways, energy is delivered for 5 to 10 seconds at a temperature in the range of 60 to 70 degrees C. For mere temporary relief or enlargement of the airway, energy is delivered for up to 5 seconds at a temperature of 55 to 80 degrees C. Additionally, the power supply may operate in impedance control mode.


The operator may start at low values of power, temperature and time, and treat until the desired effect (for example, airway diameter increasing or tissue blanching) is acutely observed, raising the power, temperature or time as needed.


Notably, the methods of the invention may be performed while the lung is experiencing natural symptoms of reversible obstructive pulmonary disease. One such example is where an individual, experiencing an asthma attack, or acute exacerbation of asthma or COPD, undergoes treatment to improve the individual's ability to breath. In such a case, the treatment provides immediate relief for (i.e., “rescues”) the patient.


All of the features disclosed in the specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.


Each feature disclosed, in this specification (including any accompanying claims, abstract and drawings), may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.


The invention is not restricted to the details of the foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

Claims
  • 1. A method for treating a subject, the method comprising: moving an elongate assembly along a lumen of an airway of a bronchial tree, wherein the elongate assembly includes an expandable distal energy delivery portion having an electrically conductive region defined by an electrically nonconductive portion; andby delivering energy with the energy delivery portion, damaging nerve tissue of a nerve trunk extending along the airway to attenuate nervous system signals transmitted to a portion of the bronchial tree.
  • 2. The method of claim 1, wherein damaging the nerve tissue comprises irreversibly damaging the nerve tissue to at least partially block a transmission of nervous system signals and to cause a decrease in smooth muscle tone of the portion of the bronchial tree.
  • 3. The method of claim 1, wherein damaging the nerve tissue comprises: destroying a section of the nerve tissue using the delivered energy such that the destroyed section impedes transmission of nervous system signals traveling along the nerve tissue.
  • 4. The method of claim 1, further comprising: terminating energy delivery;moving the distal energy delivery portion in the airway to a second location; anddamaging nerve tissue at the second location.
  • 5. The method of claim 1, wherein damaging nerve tissue comprises heating an electrode of the distal energy delivery portion to a temperature of approximately 60 to 80 degrees C.
  • 6. The method of claim 1, wherein damaging nerve tissue reduces a resting tone of smooth muscle of the airway so as to substantially increase airflow into and out of a lung of the subject.
  • 7. The method of claim 1, wherein damaging nerve tissue comprises decreasing a resistance to airflow within the bronchial tree.
  • 8. The method of claim 1, wherein damaging nerve tissue comprises delivering RF energy to the airway.
  • 9. The method of claim 1, further comprising a plurality of electrodes spaced about the distal energy delivery portion.
  • 10. The method of claim 9, wherein the plurality of electrodes are radially spaced about the distal energy delivery portion and extend longitudinally.
  • 11. A method for treating a subject, the method comprising: moving an elongate assembly along a lumen of an airway of a bronchial tree, wherein the elongate assembly includes a distal energy delivery portion having a plurality of electrodes spaced about the distal energy delivery portion; andby delivering energy with the energy delivery portion, damaging nerve tissue of a nerve trunk extending along the airway to attenuate nervous system signals transmitted to a portion of the bronchial tree;terminating energy delivery;moving the distal energy delivery portion to a second location in the bronchial tree; anddamaging nerve tissue at the second location.
  • 12. The method of claim 11, wherein the plurality of electrodes are radially spaced about the distal energy delivery portion and extend longitudinally.
  • 13. The method of claim 11, wherein damaging nerve tissue comprises heating the plurality of electrodes to a temperature of approximately 60 to 80 degrees C.
  • 14. The method of claim 11, wherein damaging nerve tissue reduces a resting tone of smooth muscle of the airway so as to substantially increase airflow into and out of a lung of the subject.
  • 15. The method of claim 11, wherein damaging nerve tissue comprises decreasing a resistance to airflow within the bronchial tree.
  • 16. The method of claim 11, wherein damaging nerve tissue comprises delivering RF energy to the airway.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 12/727,156, filed Mar. 18, 2010, now U.S. Pat. No. 8,161,978, which is a continuation of U.S. patent application Ser. No. 11/117,905, filed Apr. 29, 2005, now U.S. Pat. No. 7,740,017 which is: (a) a continuation application of U.S. application Ser. No. 09/999,851, filed Oct. 25, 2001, now U.S. Pat. No. 7,027,869, which is a continuation-in-part application of U.S. application Ser. No. 09/296,040, filed Apr. 21, 1999, now U.S. Pat. No. 6,411,852, each of which is herein incorporated by reference in their entirety; (b) a continuation-in-part application of U.S. application Ser. No. 09/436,455, filed Nov. 8, 1999, now U.S. Pat. No. 7,425,212, which is incorporated by reference herein in its entirety; and (c) a continuation-in-part application of 10/232,909, filed on Aug. 30, 2002, now U.S. Pat. No. 7,556,624, which is a continuation of U.S. Application Ser. No. 09/349,715, filed Jul. 8, 1999, now U.S. Pat. No. 6,488,673, each of which is herein incorporated by reference in their entirety. U.S. application Ser. No. 09/999,851, now U.S. Pat. No. 7,027,869, is also a continuation-in-part application of U.S. application Ser. No. 09/535,856, filed on Mar. 27, 2000, now U.S. Pat. No. 6,634,363, which is also incorporated herein by reference in its entirety. The present application is related to U.S. application Ser. No. 09/095,323 filed Jun. 10, 1998, now abandoned; U.S. application Ser. No. 09/260,401 filed on Mar. 1, 1999, now U.S. Pat. No. 6,283,988; U.S. application Ser. No. 09/003,750 filed Jan. 7, 1998, now U.S. Pat. No. 5,972,026; and U.S. application Ser. No. 08/833,550 filed Apr. 7, 1997, now U.S. Pat. No. 6,273,907 B1, the entireties of which are incorporated herein by reference.

US Referenced Citations (523)
Number Name Date Kind
612724 Hamilton Oct 1898 A
1155169 Starkweather Sep 1915 A
1207479 Bisgaard Dec 1916 A
1216183 Swingle Feb 1917 A
2072346 Smith Mar 1937 A
3320957 Sokolik May 1967 A
3568659 Karnegis Mar 1971 A
3667476 Muller Jun 1972 A
3692029 Adair Sep 1972 A
3995617 Watkins et al. Dec 1976 A
4095602 Leveen Jun 1978 A
4116589 Rishton Sep 1978 A
4129129 Amrine Dec 1978 A
4154246 LeVeen May 1979 A
4461283 Doi Jul 1984 A
4502490 Evans et al. Mar 1985 A
4503855 Maslanka Mar 1985 A
4512762 Spears Apr 1985 A
4522212 Gelinas et al. Jun 1985 A
4557272 Carr Dec 1985 A
4565200 Cosman Jan 1986 A
4567882 Heller Feb 1986 A
4584998 McGrail Apr 1986 A
4612934 Borkan Sep 1986 A
4621642 Chen Nov 1986 A
4621882 Krumme Nov 1986 A
4625712 Wampler Dec 1986 A
4643186 Rosen et al. Feb 1987 A
4646737 Hussein et al. Mar 1987 A
4674497 Ogasawara Jun 1987 A
4683890 Hewson Aug 1987 A
4704121 Moise Nov 1987 A
4706688 Don Michael et al. Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4739759 Rexroth et al. Apr 1988 A
4754065 Levenson et al. Jun 1988 A
4754752 Ginsburg et al. Jul 1988 A
4765959 Fukasawa Aug 1988 A
4773899 Spears Sep 1988 A
4779614 Moise Oct 1988 A
4784135 Blum et al. Nov 1988 A
4790305 Zoltan et al. Dec 1988 A
4799479 Spears Jan 1989 A
4802492 Grunstein Feb 1989 A
4817586 Wampler Apr 1989 A
4825871 Cansell May 1989 A
4827935 Geddes et al. May 1989 A
4846152 Wampler et al. Jul 1989 A
4862886 Clarke et al. Sep 1989 A
4895557 Moise et al. Jan 1990 A
4906229 Wampler Mar 1990 A
4907589 Cosman Mar 1990 A
4908012 Moise et al. Mar 1990 A
4920978 Colvin May 1990 A
4944722 Carriker et al. Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4967765 Turner et al. Nov 1990 A
4969865 Hwang et al. Nov 1990 A
4976709 Sand Dec 1990 A
4985014 Orejola Jan 1991 A
4991603 Cohen et al. Feb 1991 A
5009636 Wortley et al. Apr 1991 A
5009936 Yamanaka et al. Apr 1991 A
5010892 Colvin et al. Apr 1991 A
5019075 Spears et al. May 1991 A
5027829 Larsen Jul 1991 A
5030645 Kollonitsch Jul 1991 A
5036848 Hewson Aug 1991 A
5053033 Clarke Oct 1991 A
5056519 Vince Oct 1991 A
5074860 Gregory et al. Dec 1991 A
5078716 Doll Jan 1992 A
5084044 Quint Jan 1992 A
5096916 Skupin Mar 1992 A
5100388 Behl et al. Mar 1992 A
5100423 Fearnot Mar 1992 A
5103804 Abele et al. Apr 1992 A
5105826 Smits et al. Apr 1992 A
5106360 Ishiwara et al. Apr 1992 A
5107830 Younes Apr 1992 A
5114423 Kasprzyk et al. May 1992 A
5116864 March et al. May 1992 A
5117828 Metzger et al. Jun 1992 A
5135517 McCoy Aug 1992 A
5152286 Sitko et al. Oct 1992 A
5165420 Strickland Nov 1992 A
5167223 Koros et al. Dec 1992 A
5170803 Hewson et al. Dec 1992 A
5174288 Bardy et al. Dec 1992 A
5188602 Nichols Feb 1993 A
5191883 Lennox et al. Mar 1993 A
5213576 Abiuso et al. May 1993 A
5215103 Desai Jun 1993 A
5231996 Bardy et al. Aug 1993 A
5232444 Just et al. Aug 1993 A
5234456 Silvestrini Aug 1993 A
5254088 Lundquist et al. Oct 1993 A
5255678 Deslauriers et al. Oct 1993 A
5255679 Imran Oct 1993 A
5265604 Vince Nov 1993 A
5269758 Taheri Dec 1993 A
5281218 Imran Jan 1994 A
5292331 Boneau Mar 1994 A
5293869 Edwards et al. Mar 1994 A
5309910 Edwards et al. May 1994 A
5313943 Houser et al. May 1994 A
5324284 Imran Jun 1994 A
5343936 Beatenbough et al. Sep 1994 A
5345936 Pomeranz et al. Sep 1994 A
5366443 Eggers et al. Nov 1994 A
5368591 Lennox et al. Nov 1994 A
5370644 Langberg Dec 1994 A
5370679 Atlee, III Dec 1994 A
5374287 Rubin Dec 1994 A
5383917 Desai et al. Jan 1995 A
5393207 Maher et al. Feb 1995 A
5394880 Atlee, III Mar 1995 A
5396887 Imran Mar 1995 A
5400778 Jonson et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5411025 Webster, Jr. May 1995 A
5415166 Imran May 1995 A
5415656 Tihon et al. May 1995 A
5417687 Nardella et al. May 1995 A
5422362 Vincent et al. Jun 1995 A
5423744 Gencheff et al. Jun 1995 A
5423811 Imran et al. Jun 1995 A
5425703 Feiring Jun 1995 A
5431696 Atlee, III Jul 1995 A
5433730 Alt Jul 1995 A
5437665 Munro Aug 1995 A
5443470 Stern et al. Aug 1995 A
5454782 Perkins Oct 1995 A
5456667 Ham et al. Oct 1995 A
5458596 Lax et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5471982 Edwards et al. Dec 1995 A
5474530 Passafaro et al. Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5496271 Burton et al. Mar 1996 A
5496311 Abele et al. Mar 1996 A
5496312 Klicek Mar 1996 A
5500011 Desai Mar 1996 A
5505728 Ellman et al. Apr 1996 A
5505730 Edwards Apr 1996 A
5507791 Sit'ko Apr 1996 A
5509419 Edwards et al. Apr 1996 A
5522862 Testerman et al. Jun 1996 A
5531779 Dahl et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5545161 Imran Aug 1996 A
5545193 Fleischman et al. Aug 1996 A
5547469 Rowland et al. Aug 1996 A
5549559 Eshel Aug 1996 A
5549655 Erickson Aug 1996 A
5549661 Kordis et al. Aug 1996 A
RE35330 Malone et al. Sep 1996 E
5558073 Pomeranz et al. Sep 1996 A
5562608 Sekins et al. Oct 1996 A
5571074 Buckman, Jr. et al. Nov 1996 A
5571088 Lennox et al. Nov 1996 A
5574059 Regunathan et al. Nov 1996 A
5578072 Barone et al. Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5588812 Taylor et al. Dec 1996 A
5595183 Swanson et al. Jan 1997 A
5598848 Swanson et al. Feb 1997 A
5599345 Edwards et al. Feb 1997 A
5601088 Swanson et al. Feb 1997 A
5605157 Panescu et al. Feb 1997 A
5607419 Amplatz et al. Mar 1997 A
5607462 Imran Mar 1997 A
5620438 Amplatz et al. Apr 1997 A
5623940 Daikuzono Apr 1997 A
5624439 Edwards et al. Apr 1997 A
5626618 Ward et al. May 1997 A
5630425 Panescu et al. May 1997 A
5630794 Lax et al. May 1997 A
5634471 Fairfax et al. Jun 1997 A
5641326 Adams Jun 1997 A
5647870 Kordis et al. Jul 1997 A
5660175 Dayal Aug 1997 A
5678535 DiMarco Oct 1997 A
5680860 Imran Oct 1997 A
5681280 Rusk et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5687723 Avitall Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5693078 Desai et al. Dec 1997 A
5694934 Edelman Dec 1997 A
5695471 Wampler Dec 1997 A
5699799 Xu et al. Dec 1997 A
5702386 Stern et al. Dec 1997 A
5707218 Maher et al. Jan 1998 A
5707336 Rubin Jan 1998 A
5707352 Sekins et al. Jan 1998 A
5722401 Pietroski et al. Mar 1998 A
5722403 McGee et al. Mar 1998 A
5722416 Swanson et al. Mar 1998 A
5725525 Kordis Mar 1998 A
5727569 Benetti et al. Mar 1998 A
5728094 Edwards Mar 1998 A
5730128 Pomeranz et al. Mar 1998 A
5730704 Avitall Mar 1998 A
5730726 Klingenstein Mar 1998 A
5730741 Horzewski et al. Mar 1998 A
5735846 Panescu et al. Apr 1998 A
5740808 Panescu et al. Apr 1998 A
5741248 Stern et al. Apr 1998 A
5752518 McGee et al. May 1998 A
5755714 Murphy-Chutorian May 1998 A
5755753 Knowlton May 1998 A
5759158 Swanson Jun 1998 A
5765568 Sweezer, Jr. et al. Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5772590 Webster, Jr. Jun 1998 A
5779669 Haissaguerre et al. Jul 1998 A
5779698 Clayman et al. Jul 1998 A
5782239 Webster, Jr. Jul 1998 A
5782797 Schweich, Jr. et al. Jul 1998 A
5782827 Gough et al. Jul 1998 A
5782848 Lennox Jul 1998 A
5782899 Imran Jul 1998 A
5792064 Panescu et al. Aug 1998 A
5795303 Swanson et al. Aug 1998 A
5800375 Sweezer et al. Sep 1998 A
5807306 Shapland et al. Sep 1998 A
5810757 Sweezer, Jr. et al. Sep 1998 A
5810807 Ganz et al. Sep 1998 A
5817028 Anderson Oct 1998 A
5817073 Krespi Oct 1998 A
5820554 Davis et al. Oct 1998 A
5823189 Kordis Oct 1998 A
5827277 Edwards Oct 1998 A
5833651 Donovan et al. Nov 1998 A
5836905 Lemelson et al. Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5837001 Mackey Nov 1998 A
5843075 Taylor Dec 1998 A
5843077 Edwards Dec 1998 A
5846238 Jackson et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5848972 Triedman et al. Dec 1998 A
5849026 Zhou et al. Dec 1998 A
5855577 Murphy-Chutorian et al. Jan 1999 A
5860974 Abele Jan 1999 A
5863291 Schaer Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5868740 LeVeen et al. Feb 1999 A
5871443 Edwards et al. Feb 1999 A
5871523 Fleischman et al. Feb 1999 A
5873852 Vigil et al. Feb 1999 A
5873865 Horzewski et al. Feb 1999 A
5876340 Tu et al. Mar 1999 A
5876399 Chia et al. Mar 1999 A
5881727 Edwards Mar 1999 A
5882346 Pomeranz et al. Mar 1999 A
5891135 Jackson et al. Apr 1999 A
5891136 McGee et al. Apr 1999 A
5891138 Tu et al. Apr 1999 A
5893847 Kordis Apr 1999 A
5897554 Chia et al. Apr 1999 A
5899882 Waksman et al. May 1999 A
5904651 Swanson et al. May 1999 A
5904711 Flom et al. May 1999 A
5906636 Casscells, III et al. May 1999 A
5908445 Whayne et al. Jun 1999 A
5908446 Imran Jun 1999 A
5908839 Levitt et al. Jun 1999 A
5911218 DiMarco Jun 1999 A
5916235 Guglielmi Jun 1999 A
5919147 Jain Jul 1999 A
5919172 Golba, Jr. Jul 1999 A
5924424 Stevens et al. Jul 1999 A
5928228 Kordis et al. Jul 1999 A
5931835 Mackey Aug 1999 A
5935079 Swanson et al. Aug 1999 A
5941869 Patterson et al. Aug 1999 A
5951494 Wang et al. Sep 1999 A
5951546 Lorentzen Sep 1999 A
5954661 Greenspon et al. Sep 1999 A
5954662 Swanson et al. Sep 1999 A
5954717 Behl et al. Sep 1999 A
5957961 Maguire et al. Sep 1999 A
5964753 Edwards Oct 1999 A
5964796 Imran Oct 1999 A
5971983 Lesh Oct 1999 A
5972026 Laufer et al. Oct 1999 A
5976175 Hirano et al. Nov 1999 A
5979456 Magovern Nov 1999 A
5980563 Tu et al. Nov 1999 A
5984917 Fleischman et al. Nov 1999 A
5991650 Swanson et al. Nov 1999 A
5992419 Sterzer et al. Nov 1999 A
5993462 Pomeranz et al. Nov 1999 A
5997534 Tu et al. Dec 1999 A
5999855 DiMarco Dec 1999 A
6001054 Regulla et al. Dec 1999 A
6003517 Sheffield et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6006755 Edwards Dec 1999 A
6008211 Robinson et al. Dec 1999 A
6009877 Edwards Jan 2000 A
6010500 Sherman et al. Jan 2000 A
6014579 Pomeranz et al. Jan 2000 A
6016437 Tu et al. Jan 2000 A
6023638 Swanson Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6029091 De La Rama et al. Feb 2000 A
6033397 Laufer et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6036689 Tu et al. Mar 2000 A
6039731 Taylor et al. Mar 2000 A
6045549 Smethers et al. Apr 2000 A
6045550 Simpson et al. Apr 2000 A
6050992 Nichols Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6053909 Shadduck Apr 2000 A
6056744 Edwards May 2000 A
6056769 Epstein et al. May 2000 A
6063078 Wittkampf May 2000 A
6071280 Edwards et al. Jun 2000 A
6071281 Burnside et al. Jun 2000 A
6071282 Fleischman Jun 2000 A
6083255 Laufer et al. Jul 2000 A
6090104 Webster, Jr. Jul 2000 A
6092528 Edwards Jul 2000 A
6102886 Lundquist et al. Aug 2000 A
6106524 Eggers et al. Aug 2000 A
6123702 Swanson et al. Sep 2000 A
6123703 Tu et al. Sep 2000 A
6139527 Laufer et al. Oct 2000 A
6139571 Fuller et al. Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6143013 Samson et al. Nov 2000 A
6149647 Tu et al. Nov 2000 A
6152143 Edwards Nov 2000 A
6152899 Farley et al. Nov 2000 A
6159194 Eggers et al. Dec 2000 A
6179833 Taylor Jan 2001 B1
6183468 Swanson et al. Feb 2001 B1
6198970 Freed et al. Mar 2001 B1
6200311 Danek et al. Mar 2001 B1
6200332 Del Giglio Mar 2001 B1
6200333 Laufer Mar 2001 B1
6210367 Carr Apr 2001 B1
6212433 Behl Apr 2001 B1
6214002 Fleischman et al. Apr 2001 B1
6216043 Swanson et al. Apr 2001 B1
6216044 Kordis Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6235024 Tu May 2001 B1
6241727 Tu et al. Jun 2001 B1
6245065 Panescu et al. Jun 2001 B1
6254598 Edwards et al. Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6264653 Falwell Jul 2001 B1
6269813 Fitzgerald et al. Aug 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6273907 Laufer Aug 2001 B1
6283988 Laufer et al. Sep 2001 B1
6283989 Laufer et al. Sep 2001 B1
6287304 Eggers et al. Sep 2001 B1
6296639 Truckai et al. Oct 2001 B1
6299633 Laufer Oct 2001 B1
6322559 Daulton et al. Nov 2001 B1
6322584 Ingle et al. Nov 2001 B2
6338727 Noda et al. Jan 2002 B1
6338836 Kuth et al. Jan 2002 B1
6346104 Daly et al. Feb 2002 B2
6355031 Edwards et al. Mar 2002 B1
6379352 Reynolds et al. Apr 2002 B1
6409723 Edwards Jun 2002 B1
6411852 Danek et al. Jun 2002 B1
6416511 Lesh et al. Jul 2002 B1
6416740 Unger Jul 2002 B1
6425895 Swanson et al. Jul 2002 B1
6440129 Simpson Aug 2002 B1
6442435 King et al. Aug 2002 B2
6458121 Rosenstock et al. Oct 2002 B1
6460545 Kordis Oct 2002 B2
6488673 Laufer et al. Dec 2002 B1
6488679 Swanson et al. Dec 2002 B1
6493589 Medhkour et al. Dec 2002 B1
6494880 Swanson et al. Dec 2002 B1
6496738 Carr Dec 2002 B2
6514246 Swanson et al. Feb 2003 B1
6526320 Mitchell Feb 2003 B2
6529756 Phan et al. Mar 2003 B1
6544226 Gaiser et al. Apr 2003 B1
6544262 Fleischman Apr 2003 B2
6547788 Maguire et al. Apr 2003 B1
6558378 Sherman et al. May 2003 B2
6572612 Stewart et al. Jun 2003 B2
6575623 Werneth Jun 2003 B2
6575969 Rittman, III et al. Jun 2003 B1
6582427 Goble et al. Jun 2003 B1
6582430 Hall Jun 2003 B2
6589235 Wong et al. Jul 2003 B2
6610054 Edwards et al. Aug 2003 B1
6620159 Hegde Sep 2003 B2
6626903 McGuckin, Jr. et al. Sep 2003 B2
6634363 Danek et al. Oct 2003 B1
6635056 Kadhiresan et al. Oct 2003 B2
6638273 Farley et al. Oct 2003 B1
6640120 Swanson et al. Oct 2003 B1
6645200 Koblish et al. Nov 2003 B1
6652548 Evans et al. Nov 2003 B2
6669693 Friedman Dec 2003 B2
6673068 Berube Jan 2004 B1
6692492 Simpson et al. Feb 2004 B2
6699243 West et al. Mar 2004 B2
6714822 King et al. Mar 2004 B2
6723091 Goble et al. Apr 2004 B2
6743197 Edwards Jun 2004 B1
6749604 Eggers et al. Jun 2004 B1
6749606 Keast et al. Jun 2004 B2
6767347 Sharkey et al. Jul 2004 B2
6770070 Balbierz Aug 2004 B1
6802843 Truckai et al. Oct 2004 B2
6805131 Kordis Oct 2004 B2
6837888 Ciarrocca et al. Jan 2005 B2
6840243 Deem et al. Jan 2005 B2
6849073 Hoey et al. Feb 2005 B2
6852091 Edwards et al. Feb 2005 B2
6852110 Roy et al. Feb 2005 B2
6866662 Fuimaono et al. Mar 2005 B2
6881213 Ryan et al. Apr 2005 B2
6893436 Woodard et al. May 2005 B2
6893439 Fleischman May 2005 B2
6895267 Panescu et al. May 2005 B2
6904303 Phan et al. Jun 2005 B2
6917834 Koblish et al. Jul 2005 B2
6939346 Kannenberg et al. Sep 2005 B2
6954977 Maguire et al. Oct 2005 B2
7027869 Danek et al. Apr 2006 B2
7043307 Zelickson et al. May 2006 B1
7104987 Biggs et al. Sep 2006 B2
7104990 Jenkins et al. Sep 2006 B2
7118568 Hassett et al. Oct 2006 B2
7122033 Wood Oct 2006 B2
7131445 Amoah Nov 2006 B2
7186251 Malecki et al. Mar 2007 B2
7198635 Danek et al. Apr 2007 B2
7200445 Dalbec et al. Apr 2007 B1
7241295 Maguire Jul 2007 B2
7255693 Johnston et al. Aug 2007 B1
7264002 Danek et al. Sep 2007 B2
7266414 Cornelius et al. Sep 2007 B2
7273055 Danek et al. Sep 2007 B2
7425212 Danek et al. Sep 2008 B1
7542802 Biggs et al. Jun 2009 B2
7556624 Laufer et al. Jul 2009 B2
7740017 Danek et al. Jun 2010 B2
7770584 Danek et al. Aug 2010 B2
8088127 Mayse et al. Jan 2012 B2
8161978 Danek et al. Apr 2012 B2
8172827 Deem et al. May 2012 B2
8226638 Mayse et al. Jul 2012 B2
20030050631 Mody et al. Mar 2003 A1
20030065371 Satake Apr 2003 A1
20030069570 Witzel et al. Apr 2003 A1
20030187430 Vorisek Oct 2003 A1
20030236455 Swanson et al. Dec 2003 A1
20040049175 Speck et al. Mar 2004 A1
20040153056 Muller et al. Aug 2004 A1
20040249401 Rabiner et al. Dec 2004 A1
20050010270 Laufer Jan 2005 A1
20050096644 Hall et al. May 2005 A1
20050171396 Pankratov et al. Aug 2005 A1
20050193279 Daners Sep 2005 A1
20050203503 Edwards et al. Sep 2005 A1
20050240176 Oral et al. Oct 2005 A1
20050251128 Amoah Nov 2005 A1
20060062808 Laufer et al. Mar 2006 A1
20060079887 Buysse et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060135953 Kania et al. Jun 2006 A1
20060137698 Danek et al. Jun 2006 A1
20060247617 Danek et al. Nov 2006 A1
20060247618 Kaplan et al. Nov 2006 A1
20060247619 Kaplan et al. Nov 2006 A1
20060247726 Biggs et al. Nov 2006 A1
20060247727 Biggs et al. Nov 2006 A1
20060247746 Danek et al. Nov 2006 A1
20060254600 Danek et al. Nov 2006 A1
20060278243 Danek et al. Dec 2006 A1
20060278244 Danek et al. Dec 2006 A1
20060282071 Utley et al. Dec 2006 A1
20070074719 Danek et al. Apr 2007 A1
20070083194 Kunis et al. Apr 2007 A1
20070083197 Danek et al. Apr 2007 A1
20070100390 Danaek et al. May 2007 A1
20070102011 Danek et al. May 2007 A1
20070106292 Kaplan et al. May 2007 A1
20070106296 Laufer et al. May 2007 A1
20070106339 Errico et al. May 2007 A1
20070106348 Laufer May 2007 A1
20070118184 Danek et al. May 2007 A1
20070118190 Danek et al. May 2007 A1
20070123958 Laufer May 2007 A1
20070123961 Danek et al. May 2007 A1
20070129720 Demarais et al. Jun 2007 A1
20070162085 DiLorenzo Jul 2007 A1
20080004596 Yun et al. Jan 2008 A1
20080097424 Wizeman et al. Apr 2008 A1
20080132886 Cohen et al. Jun 2008 A1
20080255642 Zarins et al. Oct 2008 A1
20090018538 Webster et al. Jan 2009 A1
20090030477 Jarrard Jan 2009 A1
20090043301 Jarrard et al. Feb 2009 A1
20090069797 Danek et al. Mar 2009 A1
20090143705 Danek et al. Jun 2009 A1
20090143776 Danek et al. Jun 2009 A1
20090192505 Askew et al. Jul 2009 A1
20090192508 Laufer et al. Jul 2009 A1
20090306644 Mayse et al. Dec 2009 A1
20100160906 Jarrard Jun 2010 A1
20100204689 Danek et al. Aug 2010 A1
20110118725 Mayse et al. May 2011 A1
20110152855 Mayse et al. Jun 2011 A1
20110257647 Mayse et al. Oct 2011 A1
Foreign Referenced Citations (51)
Number Date Country
19529634 Feb 1997 DE
189329 Jun 1987 EP
286145 Oct 1988 EP
280225 Mar 1989 EP
286145 Oct 1990 EP
282225 Jun 1992 EP
908713 Apr 1999 EP
908150 May 2003 EP
768091 Jul 2003 EP
1297795 Aug 2005 EP
2659240 Jul 1997 FR
59167707 Sep 1984 JP
7289557 Nov 1995 JP
9047518 Feb 1997 JP
9243837 Sep 1997 JP
10026709 Jan 1998 JP
2053814 Feb 1996 RU
2091054 Sep 1997 RU
545358 Feb 1977 SU
WO8911311 Nov 1989 WO
WO9502370 Jan 1995 WO
WO9510322 Apr 1995 WO
WO9604860 Feb 1996 WO
WO9610961 Apr 1996 WO
WO9732532 Sep 1997 WO
WO9733715 Sep 1997 WO
WO9737715 Oct 1997 WO
WO9740751 Nov 1997 WO
WO9844854 Oct 1998 WO
WO9852480 Nov 1998 WO
WO9856324 Dec 1998 WO
WO9903413 Jan 1999 WO
WO9858681 Mar 1999 WO
WO9913779 Mar 1999 WO
WO9932040 Jul 1999 WO
WO9934741 Jul 1999 WO
WO9944506 Sep 1999 WO
WO9945855 Sep 1999 WO
WO9964109 Dec 1999 WO
WO0051510 Sep 2000 WO
WO0062699 Oct 2000 WO
WO0103642 Jan 2001 WO
WO0232333 Apr 2002 WO
WO0232334 Apr 2002 WO
WO2007053230 May 2007 WO
WO2009082433 Jul 2009 WO
WO2009137819 Nov 2009 WO
WO2011056684 May 2011 WO
WO2011060200 May 2011 WO
WO2011060201 May 2011 WO
WO2011127216 Oct 2011 WO
Non-Patent Literature Citations (66)
Entry
An S. S., et al., “Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma,” European Respiratory Journal, 2007, 29 (5), 834-860.
Awadh N., et al., “Airway wall thickness in patients with near fatal asthma and control groups: assessment with high resolution computed tomographic scanning,” Thorax, 1998, 53, 248-253.
Bel, et al., “Hot stuff”: bronchial thermoplasty for asthma, American Journal of Respiratory and Critical Care Medicine, 2006, 173, 941-943.
Brown R. H., et al., “Effect of bronchial thermoplasty on airway distensibility,” European Respiratory Journal, 2005, 26 (2), 277-282.
Brown R. H., et al., “In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography,” Journal of Applied Physiology, 2005, 98, 1603-1606.
Chhajed P., et al., “Will there be a role for bronchoscopic radiofrequency ablation?,” J Bronchol, 2005, 12 (3), 184-186.
Co-pending U.S. Appl. No. 09/095,323.
Co-pending U.S. Appl. No. 09/244,173.
Cox G., et al., “Asthma Control during the Year after Bronchial Thermoplasty,” The New England journal of medicine, 2007, 356 (13), 1327-1337.
Cox G., et al., “Asthma Intervention Research (AIR) Trial Evaluating Bronchial Thermoplasty™: Early Results, American Thoracic Society Annual Meeting,” 2002, 1 page.
Cox G., et al., “Bronchial Thermoplasty for Asthma,” American Journal of Respiratory and Critical Care Medicine, 2006, 173, 965-969.
Cox G., et al., “Bronchial Thermoplasty: Long-Term Follow-Up and Patient Satisfaction,” Chest, 2004, 126 (4), 822s.
Cox G., et al., “Bronchial Thermoplasty: One-Year Update, American Thoracic Society Annual Meeting,” Am J Respir Crit Care Med, 2004, 169, A313.
Cox G., et al., “Clinical Experience With Bronchial Thermoplasty for the Treatment of Asthma,” Chest, 2003, 124, 106S.
Cox G., et al., “Development of a Novel Bronchoscopic Therapy for Asthma,” Journal of Allergy and Clinical Immunology, 2003, 113 (2), S33.
Cox G., et al., “Early Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma, American Thoracic Society Annual Meeting,” 2002, 1068.
Cox G., et al., “Impact of bronchial thermoplasty on asthma status: interim results from the AIR trial.European Respiratory Society Annual Meeting. Munich, Germany,” 2006, 1 page.
Cox G., et al., “Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations,” European Respiratory Journal, 2004, 24, 659-663.
Danek C. J., et al., “Bronchial thermoplasty reduces canine airway responsiveness to local methacholine challenge, American Thoracic Society Annual Meeting,” 2002, 1 page.
Danek C. J., et al., “Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs,” J Appl Physiol, 2004, 97, 1946-1953.
Dierkesmann, et al., “Indication and Results of Endobronchial Laser Therapy,” Lung, 1990, 168, 1095-1102.
Erle C. H., et al., “Botulinum toxin: a novel therapeutic option for bronchial asthma?,” Medical Hypotheses, 2006, 66, 915-919.
Global Strategy for Asthma Management and Prevention, NIH, National Heart ,Lung and Blood Institute, 2002, 192 Pages Total.
Hogg J. C., “The Pathology of Asthma,” APMIS, 1997, 105 (10), 735-745.
Ivanyuta O. M., et al., “Effect of Low-Power Laser Irradiation of Bronchial Mucosa on the State of Systemic and Local Immunity in Patients with Chronic Bronchitis,” Problemy Tuberkuleza, 1991, 6, 26-29.
James, et al., “The Mechanics of Airway Narrowing in Asthma,” Am. Rev. Respir. Dis., 1989, 139, 242-246.
Janssen L. J., “Asthma therapy: how far have we come, why did we fail and where should we go next?,” Eur Respir J, 2009, 33, pp. 11-20.
Johnson S. R., et al., “Synthetic Functions of Airway Smooth Muscle in Asthma,” Trends Pharmacol. Sci., 1997, 18 (8), 288-292.
Julian Solway M. D., et al., “Airway Smooth Muscle as a Target for Asthma Therapy,” The New England journal of medicine, 2007, 356 (13), 1367-1369.
Kitamura S., “Color Atlas of Clinical Application of Fiberoptic Bronchoscopy,” 1990, Year Book Medical Publishers, 17.
Kraft M., “The distal airways: are they Important in asthma?,” European Respiratory, 1999, 1403-1417.
Laviolette, et al., “Asthma Intervention Research (Air) Trial: Early Safety Assessment of Bronchial Thermoplasty,” Am J Respir Crit Care Med, 2004, 169, A314.
Leff, et al., Bronchial Thermoplasty Alters Airway Smooth Muscle and Reduces Responsiveness in Dogs: A Possible Procedure for the Treatment of Asthma, American Thoracic Society Annual Meeting 2002, 1 page.
Lombard, et al., “Histologic Effects of Bronchial Thermoplasty of Canine and Human Airways, American Thoracic Society Annual Meeting,” 2002, 1 page.
Macklem P. T., “Mechanical Factors Determining Maximum Bronchoconstriction,” European Respiratory Journal, 1989, 6, 516s-519s.
Martin N., et al, “Bronchial Thermoplasty for the Treatment of Asthma,” Current Allergy and Asthma Reports, 2009, 9 (1), 88-95.
Mayse M. L., et al., “Clinical Pearls for Bronchial Thermoplasty,” J Bronchol, 2007, 14 (2), 115-123.
Miller J. D., et al., “A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway,” 2005, 127, 1999-2006.
Miller J. D., et al., “Bronchial Thermoplasty Is Well Tolerated by Non-Asthmatic Patients Requiring Lobectomy, American Thoracic Society Annual Meeting,” 2002, 1 page.
Netter F. H., “Respiratory System: A Compilation of Paintings Depicting Anatomy and Embryology, Physiology, Pathology, Pathophysiology, and Clinical Features and Treatment of Diseases,In The CIBA Collection of Medical Illustrations M.B. Divertie, ed., Summit: New Jerse,” 1979, 7, 119-135.
Notice of final Rejection, Japanese Patent Application No. 2000-553172, dated Sep. 2, 2008, 5 pages.
PCT International search report for application No. PCT/US00/05412 mailed on Jun. 20, 2000, 2 pages.
PCT International search report for application No. PCT/US00/18197 mailed on Oct. 3, 2000, 1 page.
PCT International search report for application No. PCT/US00/28745 mailed on Mar. 28, 2001, 6 pages.
PCT International search report for application No. PCT/US01/32321 mailed on Jan. 18, 2002, 2 pages.
PCT International search report for application No. PCT/US98/03759 mailed on Jul. 30, 1998, 1 page.
PCT International search report for application No. PCT/US98/26227 mailed on Mar. 25, 1999, 1 page.
PCT International search report for application No. PCT/US99/00232 mailed on Mar. 4, 1999, 1 page.
PCT International search report for application No. PCT/US99/12986 mailed on Sep. 29, 1999, 1 page.
Peter K. Jeffery, “Remodeling in Asthma and Chronic Obstructive Lung Disease,” American Journal of Respiratory and Critical Care Medicine, 2001, 164 (10), 13516.
Provotorov, et al., “The Clinical Efficacy of Treating Patients with Nonspecific Lung Disease by Using Low-energy Laser Irradiation and Intrapulmonary Drug Administration, ISSN: 0040-3660,” Terapevticheskii Arkhiv (USSR), 1991, 62 (12), 18-23.
Rubin, et al., “Bronchial thermoplasty improves asthma status of moderate to severe perisstent asthmatics over and above current standard-of-care, American College of Chest Physicians,” 2006, 2 pages.
Seow C. Y., et al., “Signal Transduction in Smooth Muscle Historical perspective on airway smooth muscle: the saga of a frustrated cell,” J Appl Physiol, 2001, 91, 938-952.
Shesterina M. V., et al., “Effect of laser therapy on immunity in patients with bronchial asthma and pulmonary tuberculosis,” 1993, 23-26.
Stephanie A.Shore, “Airway Smooth Muscle in Asthma—Not Just More of the Same,” N Engl J Med, 2004, 351 (6), 531-532.
Sterk P. J., et al., “Heterogeneity of airway hyperresponsiveness: time for unconventional, but traditional, studies,” J Appl Physiol, 2004, 96, 2017-2018.
Toma, et al., “Brave new world for interventional bronchoscopy,” Thorax, 2005, 60, 180-181.
Trow T., “Clinical Year in Review I Diagnostic Imaging, Asthma, Lung Transplantation, and Interventional Pulmonology,” Proceedings of the American Thoracic Society, 2006, 3, 553-556.
UNSW Embryo—Respiratory System [online], Embryology, 2007, [retrieved on Dec. 10, 2007]. Retrieved from the intemet: (URL:http://embryology.med.unsw.edu.au/Refer/respire/sclect.htm).
Vasilotta P. L., et al., “I-R Laser: A new therapy in Rhino-Sino-Nasal bronchial syndrome with asthmatic component,” American Society for Laser medicine and Surgery abstracts, 74.
Vorotnev, et al., “Low energy laser treatment of chronic obstructive bronchitis in a general rehabilitation center,ISSN: 0040-3660,” Terapevticheskii Arkhiv, 1997, 69 (3), 17-19.
Wayne Mitzner, “Airway Smooth Muscle the appendix of the Lung,” American Journal of Respiratory and Critical Care Medicine, 2004, 169, 787-790.
Wayne Mitznerl, “Bronchial Thermoplasty in Asthma,” Allergology International, 2006, 55, 225-234.
Wiggs B. R., et al., “On the Mechanism of Mucosal Folding in Normal and Asthmatic Airways,” J. Appl. Physiol., 1997, 83 (6), 1814-1821.
Wilson S. R., et al., “Global assessment after bronchial thermoplasty: the patients perspective,” Journal of Outcomes Research, 2006, 10, 37-46.
Wizeman, et al., “A Computer Model of Thermal Treatment of Airways by Radiofrequency (RF) Energy Delivery, American Thoracic Society Annual Meeting,” 2007, 1 page.
Related Publications (1)
Number Date Country
20110079230 A1 Apr 2011 US
Continuations (4)
Number Date Country
Parent 12727156 Mar 2010 US
Child 12964678 US
Parent 11117905 Apr 2005 US
Child 12727156 US
Parent 09999851 Oct 2001 US
Child 11117905 US
Parent 09349715 Jul 1999 US
Child 10232909 US
Continuation in Parts (4)
Number Date Country
Parent 09296040 Apr 1999 US
Child 09999851 US
Parent 09436455 Nov 1999 US
Child 11117905 US
Parent 10232909 Aug 2002 US
Child 09436455 US
Parent 09535856 Mar 2000 US
Child 09999851 US